Imugene Limited (ASX:IMU) Announces Positive Phase 1b Trial Results for Azer-cel
Imugene Limited (ASX:IMU) reports 75% response rate in Phase 1b trial of azer-cel for relapsed diffuse large B-cell lymphoma.
Category: ASX-IMU
Imugene Limited
Imugene Limited (ASX:IMU) Receives $5.8m R&D Tax Refund
Imugene Limited (ASX:IMU) receives a A$5.8m R&D tax refund to advance its immuno-oncology pipeline.
Imugene Limited (ASX:IMU) Announces Extraordinary General Meeting
Imugene Limited (ASX:IMU) announces an Extraordinary General Meeting to discuss share consolidation and the issuance of new shares to support its clinical projects.
Imugene Limited (ASX:IMU) Granted FDA Fast Track Designation for Azer-cel
Imugene Limited (ASX:IMU) secures FDA Fast Track designation for its allogeneic CAR T-cell therapy azer-cel, advancing treatment for relapsed or refractory diffuse large B-cell lymphoma.